Urgent.News

What's breaking now, across thousands of outlets.

Business

Merck Signs $2.13 Bln License Deal With SciBrunch Therapeutics For KRAS G12D Inhibitor

(RTTNews) - Merck & Co., Inc. (MRK), an American multinational pharmaceutical company, announced on Monday that it has entered into an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at nasdaq.com →

More in Business

Claimant law firms seek appeal in Diesel emissions legal battle

A group of car manufacturing giants may be forced back to the High Court to defend allegations that they installed devices to curb diesel emissions tests. In the case nicknamed ‘Dieselgate’, the High Court handed down a judgment in July ruling in favour of the carmakers, but claimants, over a million motorists, a law firm [...]

More from Monday 28 September →